The community for GLP-1 answers
and everyday remedies.
Ask real people about semaglutide side effects, tirzepatide dosing, natural alternatives like berberine, and the everyday remedies you actually search for. Every dictionary entry is sourced from openFDA, RxNorm, MedlinePlus and ClinicalTrials.gov.
remedy.med is a community discussion platform, not medical advice. Content is user-generated and not verified by medical professionals. Consult a licensed healthcare provider before trying any remedy, especially if pregnant, on medication, or managing a chronic condition.
Every major GLP-1, cross-referenced
Indications, warnings, and natural adjuncts — sourced, not sponsored.
What's new: FDA labels, recalls & clinical trials
Live pulled from openFDA and ClinicalTrials.gov — refreshed every 30 minutes.
- Trial· ClinicalTrials.gov2026-08-18
A Study of the Intestinal Microbiota in Children and Adolescents With Eating Disorders. A Perspective From Psychoneuroimmunology
The goal of this observational study is to learn if behavioral and psychological factors are associated with the intestinal microbiota composition and function in children and adolescents with eating disorders (ED). The main questions it ai
- Trial· ClinicalTrials.gov2026-08-18
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
This is a Phase 1/2a double-blind dose-escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-INHBE in adult participants with obesity (in Part 1), the saf
- Trial· ClinicalTrials.gov2026-08-18
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
The purpose of this study is to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.
- Trial· ClinicalTrials.gov2026-08-17
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
This phase II trial compares the effect of time-restricted eating (TRE) and glucagon-like peptide-1 (GLP1) receptor agonists (RA), semaglutide and tirzepatide, to an American Heart Association (AHA) heart healthy diet (HHD) intervention on
- Trial· ClinicalTrials.gov2026-08-14
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weig
- Trial· ClinicalTrials.gov2026-08-14
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weig
- FDA label· openFDA Drug Label2026-07-30
Updated FDA label: Ozempic (SEMAGLUTIDE)
1 INDICATIONS AND USAGE OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infa
- FDA label· openFDA Drug Label2026-07-29
Updated FDA label: MOUNJARO (TIRZEPATIDE)
1 INDICATIONS AND USAGE MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. MOUNJARO ® is a glucose-dependent insulinotropic polypeptid
- FDA label· openFDA Drug Label2026-07-27
Updated FDA label: Liraglutide (LIRAGLUTIDE)
1 INDICATIONS AND USAGE Liraglutide Injection is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Limitations of Use : Liraglutide Injection contai
- FDA label· openFDA Drug Label2026-06-16
Updated FDA label: Trulicity (DULAGLUTIDE)
1 INDICATIONS AND USAGE TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events
- Recall· openFDA Enforcement2022-04-05
Trulicity (dulaglutide) injection, 0.75 mg/0.5mL once weekly, 4 Single-Dose Pens, Rx only,
TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions — Class Class II · Cardinal Health Inc.
- Recall· openFDA Enforcement2022-04-05
Trulicity (dulaglutide) injection, 1.5 mg/0.5mL once weekly, 4 Single-Dose Pens, Rx only,
TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions due to inclement weather. — Class Class II · Cardinal Health Inc.
Browse everyday remedies
Herbs, supplements, OTC drugs, and home remedies for the questions you actually search.